A Chinese Clinical Trial Registry:

The vaccine clinical trial involved 2,128 volunteers aged 3 and above, which started on April 29, 2020. The vaccine receivers inoculated with two injections in different procedures and doses have produced high titers of antibodies.

Sinopharm said that the candidate demonstrated a good safety profile so far, with the trial participants still under observation. The results revealed a good safety record, with no cases of severe adverse effects found in the clinical trials. For those receiving two middle-dose injections at intervals of 14 days and 21 days, the seroconversion rate of neutralizing antibodies reached 97.6 percent. For those receiving two middle-dose injections at an interval of 28 days, the seroconversion rate of neutralizing antibodies reached 100 percent.